Currently viewing: Consolidated statement of changes in equity / Next: Consolidated statement of cash flows

Consolidated statement of changes in equity

for the year ended 30 September 2021
Attributable to equity holders of the Company 
Stated 
capital 
R'm
 
Other 
reserves 
R'm
 
FCTR 
R'm
 
Retained 
earnings 
R'm
 
Reserves 
R'm
 
Non- 
controlling 
interest 
R'm 
Total 
equity 
R'm
 
Balance at 1 October 2020  13 531  (787) 2 348  1 966  3 527  1 220  18 278 
Total comprehensive income/(loss) for the year  –  44  (880) 1 754  918  72  990 
  Profit for the year  –  –  –  1 754  1 754  100  1 854 
  Other comprehensive income/(loss) –  44  (880) –  (836) (28) (864)
Transactions with non-controlling interests  –  14  –  –  14  (16) (2)
Distributions to shareholders  –  –  –  –  –  (171) (171)
Purchase of treasury shares for staff benefit schemes  (31) –  –  –  –  –  (31)
Vesting of treasury shares for staff benefit schemes  65  (54) –  –  (54) –  11 
Long-term incentive schemes charge  –  43  –  –  43  –  43 
Life Healthcare employee share trust charge  –  53  –  –  53  –  53 
Balance at 30 September 2021  13 565  (687) 1 468  3 720  4 501  1 105  19 171 
Notes  19 
Balance at 1 October 20191  13 515  (698) 534  2 837  2 673  1 303  17 491 
Total comprehensive income/(loss) for the year  –  (13) 1 814  (93) 1 708  150  1 858 
  (Loss)/profit for the year  –  –  –  (93) (93) 131  38 
  Other comprehensive (loss)/income  –  (13) 1 814  –  1 801  19  1 820 
Transactions with non-controlling interests  –  (108) –  –  (108) (34) (142)
Distributions to shareholders  –  –  –  (778) (778) (199) (977)
Purchase of treasury shares for staff benefit schemes  (44) –  –  –  –  –  (44)
Vesting of treasury shares for staff benefit schemes  60  (56) –  –  (56) –  4 
Long-term incentive schemes charge  –  34  –  –  34  –  34 
Life Healthcare employee share trust charge  –  54  –  –  54  –  54 
Balance at 30 September 2020  13 531  (787) 2 348  1 966  3 527  1 220  18 278 
Notes  19 
1 There was no net impact on retained earnings on 1 October 2019 as a result of adopting IFRS 16.

The accompanying notes are an integral part of these consolidated financial statements.